[Prophylaxis and treatment of cytomegalovirus infection in allogeneic bone marrow transplantation].
OBJECTIVE
To assess the efficacy and safety of Cymevene (ganciclovir) in the prophylaxis and treatment of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (allo-BMT).


METHODS
Sixty patients with leukemia undergoing allo-BMT were observed. Cymevene was given prophylactically to 20 patients at a dose of 5 mg/kg twice daily from day -9 to day -2 and restarted when the ANC > or = 1.0 x 10(9)/L and BPC > or = 30 x 10(9)/L at a daily dose of 5 mg/kg for 5 days every week until day +100. In diagnosed symptomatic CMV infections, the dose of Cymevene was 5 mg/kg twice daily for 2-3 weeks followed by 5 mg/kg twice a day for 5 days every week for an additional 2-3 weeks.


RESULTS
The incidence of active CMV infection was 0 in the prophylaxis-treated patients and 25% in the controls (P < 0.05). In diagnosed CMV diseases, marked improvement was noted in 17 of 20 patients (85%) treated with Cymevene. The most common adverse events of Cymevene were leukopenia and thrombocytopenia, but were reversible.


CONCLUSIONS
Cymevene is effective and safe for the prophylaxis and treatment of CMV infections after allo-BMT.
Guo
N
N
Institute of Hematology, People's Hospital, Beijing Medical University, Beijing 100044.
Lu
D
D
Liu
D
D
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D000998:Antiviral Agents; D015774:Ganciclovir